|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of endoscopic ultrasound in the screening and follow-up of high-risk individuals for familial pancreatic cancer显示文摘Managing familial pancreatic cancer(FPC)is challenging for gastroenterologists,surgeons and oncologists.High-risk individuals(HRI)for pancreatic cancer(PC)(FPC or with germline mutations)are a heterogeneous group of subjects with a theoretical lifetime cumulative risk of PC over 5%.Screening is mainly based on annual magnetic resonance imaging(MRI)and endoscopic ultrasound(EUS).The goal of screening is to identify early-stage operable cancers or high-risk precancerous lesions(pancreatic intraepithelial neoplasia or intraductal papillary mucinous neoplasms with high-grade dysplasia).In the literature,target lesions are identified in 2%-5%of HRI who undergo screening.EUS appears to provide better identification of small solid lesions(0%-46%of HRI)and chronicpancreatitis-like parenchymal changes(14%-77%of HRI),while MRI is probably the best modality to identify small cystic lesions(13%-49%of HRI).There are no specific studies in HRI on the use of contrast-enhanced harmonic EUS.EUS can also be used to obtain tissue samples.Nevertheless,there is still limited evidence on the accuracy of imaging procedures used for screening or agreement on which patients to treat.The cost-effectiveness of screening is also unclear.Certain new EUS-related techniques,such as searching for DNA abnormalities or protein markers in pancreatic fluid,appear to be promising. | Diane Lorenzo Vinciane Rebours Frédérique Maire Maxime Palazzo Jean-Michel Gonzalez Marie-Pierre Vullierme Alain Aubert Pascal Hammel Philippe Lévy Louis de Mestier | 2019 | World Journal of Gastroenterology2019，25，34： | 2 |
| 2 | Laparoscopic thermal ablation of splenic metastasis initial experience and present aspects 显示文摘 | Lardiere-Deguelte S de Mestier L Amroun KL | 2013 | J Visceral Surg2013，150，5： | 1 |
| 3 | Influence of spin-transfer torque on thermally activated ferromagnetic resonance excitations in magnetic tunnel junctions 显示文摘 | Petit S Mestier N de Baraduc C | 2008 | Phys Rev B2008，78，18： | 1 |
| 4 | Treatment of gastrointestinal stromaltumorswith imatinibmesylate: a major breakthrough in the understandingof tumor-specific molecular characteristics显示文摘 | De Mestier P Des Guetz G | 2005 | World J Surg2005，29，3： | 1 |
| 5 | Laparoscopic thermal ablation of splenic metastasis initial experience and present aspects显示文摘 | S. Lardière-Deguelte L. de Mestier K. Amroun J. Volet P. Cart O. Bouche A.R. Kianmanesh | 2013 | Journal of Visceral Surgery2013，，： | 1 |
| 6 | Treatment of gastrointestinal stromal tunlors with imatinib mesylate:a major breakthrough in the understanding of tumorspecific molecular characteristics 显示文摘 | De Mestier P Guetz GD | 2005 | World J Surg2005，29，： | 1 |
| 7 | Treatment of gastrointestinal stromal tumors with imatinib mesylate:a major breakthrough in the understanding of tumor-specific molecular characteristics显示文摘 | de Mestier P des Guetz G | 2005 | Word J Surg2005，29，3： | 1 |
| 8 | Treatment of gastrointestinal stromal tumours with imatinib Mesylate:a major breakthrough in the understanding of tumor-specific molecular characteristics 显示文摘 | Philippe de Mestier Gaetan des Guetz | 2005 | World J Surg2005，29，3： | 1 |
| 9 | Updating the management of patients with rectal neuroendocrine tumors显示文摘 | Louis de Mestier Hedia Brixi Rodica Gincul Thierry Ponchon Guillaume Cadiot | 2013 | Endoscopy2013，，： | 1 |
| 10 | Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review显示文摘At the time of diagnosis, 25% of patients with colorectal cancer(CRC) present with synchronous metastases, which are unresectable in the majority of patients. Whether primary tumor resection(PTR) followed by chemotherapy or immediate chemotherapy without PTR is the best therapeutic option in patients with asymptomatic CRC and unresectable metastases is a major issue, although unanswered to date. The aim of this study was to review all published data on whether PTR should be performed in patients with CRC and unresectable synchronous metastases. All aspects of the management of CRC were taken into account, es-pecially prognostic factors in patients with CRC and un-resectable metastases. The impact of PTR on survival and quality of life were reviewed, in addition to the characteristics of patients that could benefit from PTR and the possible underlying mechanisms. The risks of both approaches are reported. As no randomized study has been performed to date, we finally discussed how a therapeutic strategy's trial should be designed to pro-vide answer to this issue. | Louis de Mestier Gilles Manceau Cindy Neuzillet Jean Baptiste Bachet Jean Philippe Spano Reza Kianmanesh Jean Christophe Vaillant Olivier Bouché Laurent Han-noun Mehdi Karoui | 2014 | World Journal of Gastrointestinal Oncology2014，6，6： | 1 |
| 11 | MEK in cancer and cancer therapy显示文摘 | Neuzillet C Tijeras-Raballand A de Mestier L | 2014 | Pharmacol Ther2014，141，2： | 1 |
| 12 | Treatment of gastrointestinal stromal tumours with imatinib Mesylate: a major breakthrough in the understanding of tumor? specific molecular characteristics显示文摘 | DE MESTIER P DES GUETZ G | 2005 | World JSurg2005，29，3： | 1 |
| 13 | High c‐Met expression in stage I– II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis显示文摘 | Cindy Neuzillet Anne Couvelard Annemila? Tijeras‐Raballand Louis Mestier Armand Gramont Pierre Bédossa Valérie Paradis Alain Sauvanet Jean‐Baptiste Bachet Philippe Ruszniewski Eric Raymond Pascal Hammel Jér?me Cros | 2015 | Histopathology2015，，5： | 1 |
| 14 | News in management of colorectal cancer at JFHOD 2012 meeting 显示文摘 | Volet J de Mestier L Ehrhard F | 2012 | Bull Cancer2012，99，6： | 1 |
| 15 | Treatment of gastrointestinal stromal tumors with imatinib mesylate:a major breakthrough in the understanding of tumor-specific molecular characteristics 显示文摘 | de Mestier P des Guetz G | 2005 | World J Surg2005，29，3： | 1 |
| 16 | Treatment of gastrointestinal stromal tumorswith imatinibmesylate: a major breakthrough in the understanding of tumor - specific molecular characteristics 显示文摘 | De Mestier P Des Guetz G | 2005 | World J Surg2005，29，3： | 1 |
| 17 | MEK in cancer and cancer therapy显示文摘 | NEUZILLET C TIJERAS-RABALLAND A DE MESTIER L etal | 2014 | Pharmacol Ther2014，141，2： | 1 |
| 18 | Treatment of gastrointestinal stromal tumors with imatinib mesylate: a major breakthrough in the under- standing of tumor-specific molecular characteristics 显示文摘 | De Mestier P Des Guetz G | 2005 | World J Surg2005，29，3： | 1 |
| 19 | Treatment of gastrointestinal stromal tumors with imatinib mesylate:a major breakthrough in the understanding of tumor-specific molecular characteristics显示文摘 | De Mestier P Des Guetz G | 2005 | World J Surg2005，29，3： | 1 |
| 20 | MEK in cancerand cancer therapy 显示文摘 | Neuzillet C Tijeras-Raballand A de Mestier L | 2014 | Pharmacol Ther2014，14，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员